Vanguard Capital Wealth Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Vanguard Capital Wealth Advisors’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$404K	Buy	+2,125	New	+$365K	0.27%	74

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Vanguard Capital Wealth Advisors's IBB Position: Q2 2026 in Review

Vanguard Capital Wealth Advisors opened a new position in iShares Biotechnology ETF (IBB) in Q2 2026: 2,125 shares worth $404K. The stake represents 0.27% of the portfolio and ranks #74 among its holdings.

954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Vanguard Capital Wealth Advisors held 2,125 shares of iShares Biotechnology ETF worth $404K as of Q2 2026.
iShares Biotechnology ETF was a new Vanguard Capital Wealth Advisors position in Q2 2026.
iShares Biotechnology ETF made up 0.27% of Vanguard Capital Wealth Advisors's portfolio in Q2 2026, its #74 holding.
954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Vanguard Capital Wealth Advisors's 13F filing for Q2 2026, filed 23 Jul 2026.